- Programme Area 2
Pharmacoepidemiology
- Disease register
- Long-term safety
- Therapy effectiveness
Benefits and risks of new therapies
With the help of large clinical-epidemiological cohort studies, the Pharmacoepidemiology working group investigates the long-term safety and efficacy of new rheumatism drugs on a comparative basis. Our aim is to provide physicians and patients with reliable evidence on the safety profile under everyday conditions and thus increase the safety of therapy for risk groups.
The group is continuously developing both the technical requirements for data collection (online register, patient apps, automated monitoring) and the methodological basis for data analysis.
Team
